PADCEV plus Keytruda reduces bladder cancer recurrence risk by 47%
Go back to PADCEV plus Keytruda reduces bladder cancer recurrence risk by 47%| Astellas Pharma Inc Unsponsored ADR (AMEX: ALPMY) | Delayed: 15.69 +0.21 (1.36%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.48 | 52 Week High | $19.40 | |||
| Open | $15.76 | 52 Week Low | $12.50 | |||
| Day High | $15.76 | P/E | N/A | |||
| Day Low | $15.64 | EPS | $0.00 | |||
| Volume | 48,947 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 29.82 -0.29 (0.96%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $30.11 | 52 Week High | $37.39 | |||
| Open | $30.00 | 52 Week Low | $28.25 | |||
| Day High | $30.09 | P/E | 18.07 | |||
| Day Low | $29.69 | EPS | $1.65 | |||
| Volume | 12,571,179 | |||||



